Last reviewed · How we verify
Lu AE58054
At a glance
| Generic name | Lu AE58054 |
|---|---|
| Sponsor | H. Lundbeck A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease (PHASE3)
- Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease (PHASE1)
- Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil (PHASE3)
- Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor (PHASE3)
- Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia (PHASE2)
- Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function (PHASE1)
- Bioequivalence Study of Idalopirdine Tablets 60 mg (PHASE1)
- Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lu AE58054 CI brief — competitive landscape report
- Lu AE58054 updates RSS · CI watch RSS
- H. Lundbeck A/S portfolio CI